CTNM Stock Analysis: Buy, Sell, or Hold?
CTNM - Contineum Therapeutics, Inc. Class A Common Stock
$14.26
-0.34 (-2.33%)
▼
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Mar 05, 2026
Get Alerted When CTNM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CTNM shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: CTNM shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CTNM is currently trading at $14.26, which is considered extended relative to its 30-day fair value range of $10.15 to $13.40.
Technical Outlook: Technically, CTNM is in a strong uptrend. Immediate support is located at $11.00, while resistance sits at $14.94.
Market Sentiment: CTNM has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (16th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $20.33 (+42.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CTNM is in a strong uptrend. Immediate support is located at $11.00, while resistance sits at $14.94.
Market Sentiment: CTNM has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (16th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $20.33 (+42.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$10.15 -
$13.40
Company Quality Score
57/100
(HOLD)
Options IV Signal
16th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BEARISH: Price extended above range (+6.4% above fair value)
- BULLISH: Options cheap (IV 16th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 42.6% below Wall St target ($20.33)
Fair Price Analysis
30-Day Fair Range
$10.15 -
$13.40
Current vs Fair Value
EXTENDED
Expected Move (7 Days)
±$3.07
(21.5%)
Support & Resistance Levels
Support Level
$11.00
Resistance Level
$14.94
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
-6.49
Wall Street Target
$20.33
(+42.6%)
Last updated: February 01, 2026 6:35 AM ET
Data refreshes hourly during market hours. Next update: 7:35 AM
Data refreshes hourly during market hours. Next update: 7:35 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CTNM showing a specific setup today?
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$56 | 59 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$210 | 57 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$64 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$102 | 62 BUY |
|
ARVN
Arvinas Inc |
BUY
21 analysts |
$13 | 63 BUY |
Advanced CTNM Option Strategies
Professional options setups generated by AI based on today's CTNM price and gamma walls.
